Front Oncol. 2018 Apr 24;8:114. doi: 10.3389/fonc.2018.00114. eCollection 2018.
Yasmin-Karim S1,2,3, Moreau M2,3,4, Mueller R1,2,5, Sinha N1,2, Dabney R6, Herman A6, Ngwa W1,2,3,4.
Abstract
Over the years, many in vitro and in vivo studies have shown the antineoplastic effects of cannabinoids (CBDs), with reports advocating for investigations of combination therapy approaches that could better leverage these effects in clinical translation. This study explores the potential of combination approaches employing CBDs with radiotherapy (RT) or smart biomaterials toward enhancing therapeutic efficacy during treatment of pancreatic and lung cancers. In in vitro studies, clonogenic assay results showed greater effective tumor cell killing, when combining CBDs and RT. Meanwhile, in vivo study results revealed major increase in survival when employing smart biomaterials for sustained delivery of CBDs to tumor cells. The significance of these findings, considerations for further research, and viable roadmap to clinical translation are discussed.
KEYWORDS:
biomaterials; cancer; cannabinoids or endocannabinoids; radiotherapy; survival
- PMID: 29740535
- PMCID: PMC5928848
- DOI: 10.3389/fonc.2018.00114